{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:15:24Z","timestamp":1789964124544,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001868","name":"National Science Council of Taiwan","doi-asserted-by":"publisher","award":["MOST103-2325-B-038-002"],"award-info":[{"award-number":["MOST103-2325-B-038-002"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001868","name":"National Science Council of Taiwan","doi-asserted-by":"publisher","award":["MOST105-2314-B038-080"],"award-info":[{"award-number":["MOST105-2314-B038-080"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001868","name":"National Science Council of Taiwan","doi-asserted-by":"publisher","award":["MOST105-2320-B-038-054"],"award-info":[{"award-number":["MOST105-2320-B-038-054"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["105TMU-SHH-15"],"award-info":[{"award-number":["105TMU-SHH-15"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taipei Medical University -National Taiwan University of Science and Technology Joint Research Program","award":["TMU-NTUST-103-03"],"award-info":[{"award-number":["TMU-NTUST-103-03"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.yexcr.2018.07.017","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T01:35:43Z","timestamp":1531445743000},"page":"519-530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR\/ABL1"],"prefix":"10.1016","volume":"370","author":[{"given":"Oluwaseun Adebayo","family":"Bamodu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Tai","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hwa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Soon","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Yi","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Tai","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.yexcr.2018.07.017_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.21915","article-title":"Characterization of chronic myeloid leukemia stem cells","volume":"86","author":"Gerber","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.yexcr.2018.07.017_bib2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/BST0351347","article-title":"Characterization of cancer stem cells in chronic myeloid leukaemia","volume":"35","author":"J\u00f8rgensen","year":"2007","journal-title":"Biochem. Soc. Trans."},{"issue":"13","key":"10.1016\/j.yexcr.2018.07.017_bib3","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/pmic.201100553","article-title":"Molecular and structural characterization of the SH3 domain of AHI-1 in regulation of cellular resistance of BCR\/ABL (+) chronic myeloid leukemia cells to tyrosine kinase inhibitors","volume":"12","author":"Liu","year":"2012","journal-title":"Proteomics"},{"issue":"16","key":"10.1016\/j.yexcr.2018.07.017_bib4","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1089\/ars.2014.6096","article-title":"The implication of cancer progenitor cells and the role of epigenetics in the development of novel therapeutic strategies for chronic myeloid leukemia","volume":"22","author":"Tortorella","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.yexcr.2018.07.017_bib5","article-title":"What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?","author":"Lewis","year":"2016","journal-title":"Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.yexcr.2018.07.017_bib6","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.yexcr.2018.07.017_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1756-8722-2-31","article-title":"Vorinostat in solid and hematologic malignancies","volume":"2","author":"Siegel","year":"2009","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.yexcr.2018.07.017_bib8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/13543776.2017.1276565","article-title":"Selective histone deacetylase small molecule inhibitors: recent progress and perspectives","volume":"27","author":"Qin","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"issue":"37","key":"10.1016\/j.yexcr.2018.07.017_bib9","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.yexcr.2018.07.017_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2009.02.042","article-title":"Enhancing the apoptotic and therapeutic effects of HDAC inhibitors","volume":"280","author":"Frew","year":"2009","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.yexcr.2018.07.017_bib11","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1158\/1078-0432.CCR-14-2556","article-title":"CCR 20th anniversary commentary: vorinostat-gateway to epigenetic therapy","volume":"21","author":"Kelly","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.yexcr.2018.07.017_bib12","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nprot.2006.179","article-title":"Sulforhodamine B colorimetric assay for cytotoxicity screening","volume":"1","author":"Vichai","year":"2006","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.yexcr.2018.07.017_bib13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.yexcr.2018.07.017_bib14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1158\/2159-8290.CD-13-0235","article-title":"MEK-dependent negative feedback underlies BCR\/ABL-mediated oncogene addiction","volume":"4","author":"Asmussen","year":"2014","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.yexcr.2018.07.017_bib15","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/cdd.2011.23","article-title":"Abl interconnects oncogenic Met and p53 core pathways in cancer cells","volume":"18","author":"Furlan","year":"2011","journal-title":"Cell Death Differ."},{"issue":"11","key":"10.1016\/j.yexcr.2018.07.017_bib16","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/cas.13062","article-title":"Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies","volume":"107","author":"Imai","year":"2016","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.yexcr.2018.07.017_bib17","first-page":"129","article-title":"Treatment and molecular monitoring update in chronic myeloid leukemia management","volume":"75","author":"Sorel","year":"2017","journal-title":"Ann. Biol. Clin. (Paris)"},{"issue":"1","key":"10.1016\/j.yexcr.2018.07.017_bib18","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR\/ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.yexcr.2018.07.017_bib19","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.7150\/thno.16139","article-title":"Depletion of \u03b3-catenin by histone deacetylase inhibition confers elimination of CML stem cells in combination with imatinib","volume":"6","author":"Jin","year":"2016","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.yexcr.2018.07.017_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2040620712468289","article-title":"Management of imatinib-resistant patients with chronic myeloid leukemia","volume":"4","author":"Bhamidipati","year":"2013","journal-title":"Ther. Adv. Hematol."},{"issue":"4","key":"10.1016\/j.yexcr.2018.07.017_bib21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000353163","article-title":"Identifying the time to change BCR\/ABL inhibitor therapy in patients with chronic myeloid leukemia","volume":"130","author":"Savona","year":"2013","journal-title":"Acta Haematol."},{"issue":"355","key":"10.1016\/j.yexcr.2018.07.017_bib22","doi-asserted-by":"crossref","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined targeting of BCL-2 and BCR\/ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","author":"Carter","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.yexcr.2018.07.017_bib23","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1021\/acs.molpharmaceut.6b00872","article-title":"Codelivery of Ponatinib and SAR302503 by active bone-targeted polymeric micelles for the treatment of therapy-resistant chronic myeloid leukemia","volume":"14","author":"Mu","year":"2017","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.yexcr.2018.07.017_bib24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2141.2011.09016.x","article-title":"Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR\/ABL1 T315I gatekeeper mutation","volume":"157","author":"Coude","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.yexcr.2018.07.017_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrm.2016.8","article-title":"A decade of transcription factor-mediated reprogramming to pluripotency","volume":"17","author":"Takahashi","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.yexcr.2018.07.017_bib26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/1055-9965.EPI-13-0785","article-title":"Molecular biomarkers of cancer stem\/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers","volume":"23","author":"Mimeault","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"2","key":"10.1016\/j.yexcr.2018.07.017_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.yexcr.2018.07.017_bib28","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1593\/neo.12724","article-title":"Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR\/ABL1- independent disease progression","volume":"14","author":"Cerny-Reiterer","year":"2012","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.yexcr.2018.07.017_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s12253-016-0139-5","article-title":"Strong correlation between the expression levels of HDAC4 and SIRT6 in hematological malignancies of the adults","volume":"23","author":"Ga\u00e1l","year":"2017","journal-title":"Pathol. Oncol. Res."},{"issue":"24","key":"10.1016\/j.yexcr.2018.07.017_bib30","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1038\/sj.onc.1204336","article-title":"Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?","volume":"20","author":"Minucci","year":"2001","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.yexcr.2018.07.017_bib31","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1038\/cddis.2012.111","article-title":"Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence","volume":"3","author":"Drullion","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.yexcr.2018.07.017_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.yexcr.2018.07.017_bib33","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1053\/jhep.2001.24024","article-title":"Involvement ofp21(WAF1\/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines","volume":"33","author":"Koga","year":"2001","journal-title":"Hepatology"},{"issue":"16","key":"10.1016\/j.yexcr.2018.07.017_bib34","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1089\/ars.2014.6096","article-title":"The implication of cancer progenitor cells and the role of epigenetics in the development of novel therapeutic strategies for chronic myeloid leukemia","volume":"22","author":"Tortorella","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.yexcr.2018.07.017_bib35","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.hoc.2011.09.004","article-title":"Chronic myeloid leukemia: mechanisms of resistance and treatment","volume":"25","author":"Jabbour","year":"2011","journal-title":"Hematol. Oncol. Clin. N. Am."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482718304403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482718304403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T17:02:46Z","timestamp":1723827766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482718304403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0014482718304403"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2018.07.017","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR\/ABL1","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2018.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}